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INTRODUCTION
Epilepsies in children, especially infants, are a heteroge-
neous group of conditions that differ from epilepsies in adults
not only in the clinical manifestations of seizures but also in
etiologies and response to antiepileptic drugs (AEDs). Despite
increasing data on treatment of epilepsy, little is known about
the use of new AEDs in children especially infants with epilep-
sies, and many clinical questions need to be answered. Topi-
ramate (TPM), one of new AEDs, was first introduced in the
treatment of certain refractory epilepsy syndromes such as
Lennox-Gastaut and West syndromes and was believed to be
effective for seizure reduction without any serious or life-threat-
ening adverse events in children aged over 4 yr (1-4). How-
ever, TPM was associated with a high incidence of side effects
in clinical practice, affecting its long-term retention (5). 
The aim of this study was to assess the efficacy, tolerability,
and safety of TPM in the treatment of infants and toddlers
with partial and generalized epilepsies. This study focused
on the long-term retention rate and adverse events of TPM
compared with carbamazepine (CBZ), a conventional AED. 
MATERIALS AND METHODS
This is a long-term, open label, observational study. A total
of 146 children with epilepsy under the age of 2 yr were in-
volved in the study and were initially prescribed either TPM
or CBZ at the pediatric neurology clinic, Kyungpook Nation-
al University Hospital, Daegu, Korea from January 1, 2000
to December 31, 2003. CBZ was started with 5-10mg/kg/
day and increased weekly in increment of 5-10 mg/kg/day
to no more than 30 mg/kg/day if necessary. TPM was started
at a dose of 0.5-1 mg/kg/day and titrated to 3-9 mg/kg/day
by 1 mg/kg/day increment per week. They were on each drug
for at least 3 months or longer. The data of the long term reten-
tion and side effects of both groups, at 24, 36, and 48 months
were assessed. The data for the side effects of both AEDs were
collected from their parents’ reports and from examiners to
minimize the subjective bias. Main reasons for the discontin-
uation of both AEDs were determined by 3 scales (lack of
efficacy, adverse events, and other factors). The data were sta-
tistically analyzed using SPSS 12.0. Retention/survival rates
were estimated at 24, 36, and 48 months, using parametric
Kaplan-Meier and nonparametric Cox proportional regres-
sion methods. In analyzing side effects, a chi-square test was
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Long-term Effectiveness and Tolerability of Topiramate in Children
with Epilepsy under the Age of 2 Years: 4-Year Follow-up
This is a long-term, open label, observational study aimed to broaden our clinical
experiences in managing infants and toddlers with epilepsy. The long-term reten-
tion rate and side effects of topiramate (TPM) in them were evaluated and compared
with carbamazepine (CBZ). A total of 146 children were involved in the study (TPM=
41, CBZ=105). The retention rates at 24 , 36, and 48 months were 46.3%, 34.1%,
26.8% for TPM and 36.2%, 23.8%, 13.3% for CBZ, respectively. At 6 months after
starting antiepileptic drugs (AED), the seizure freedom or clinical efficacy (seizure
reduction rate more than 50 percent) were 73.2% for TPM and 62.9% for CBZ. The
major side effects led to discontinuation included psychomotor slowing, poor oral
intake from TPM and sleepiness and skin rash from CBZ. TPM was discontinued
due to side effects in one case (2.4%) and lack of efficacy in five cases (12.2%),
whereas CBZ was discontinued due to lack of efficacy (22.9%) and side effects
(6.7%). As compared with CBZ, TPM showed the same long-term retention rate in
children under the age of 2 yr, and no serious side effects. It is therefore conclud-
ed that TPM can be considered as a major AED for treating children with epilepsy
under the age of 2 yr.
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performed. The Institutional Review Board for the clinical
research formally approved the study (74005-940).
RESULTS
A total of 146 infants and toddlers (male 67, female 79) were
enrolled in the study. Their mean age was 8.8±5.9 months
old ranging from 1 to 23 months, the mean duration of the
follow-up was 32±24 months, and the mean duration of
medication was 24±22 months. The mean dosages were 4.9
±2.5 mg/kg/day for TPM and 12.8±3.2 mg/kg/day for
CBZ. Fifty-four patients (37%) had partial seizures, 78 pati-
ents (53.4%) had generalized seizures, and 25 patients (17.1%)
had a family history of epilepsy. Fifty-three of the 146 patients
had underlying pathology in the brain (Table 1). The clinical
characteristics were not statistically different between the two
groups. With respect to retention rates, the Kaplan-Meier
analysis of the two AEDs revealed estimated retention rates
of 46.3% for TPM and 36.2% for CBZ at 24 months, 34.1%
(TPM) and 23.8% (CBZ) at 36 months, and 26.8% (TPM),
13.3% and (CBZ) at 48 months (Figs. 1, 2). Log rank testing
showed no significant difference between the two AEDs. 
Parameters
Total
(n=146)
Topiramate
(n=41)
Carbamazepine 
(n=105)
Age (month±SD) 8.8±5.9 10.0±6.4 8.4±5.6
Sex
Male 67 (45.9%) 22 (53.7%) 45 (42.9%)
Female 79 (54.1%) 19 (46.3%) 60 (57.1%)
Seizure type
Partial 54 (37.0%) 8 (19.5%) 46 (43.8%)
Generalized 78 (53.4%) 29 (70.7%) 49 (46.7%)
Unclassified 14 (13.3%) 4 (9.8%) 10 (9.5%)
Presence of underlying  53 (36.3%) 19 (46.3%) 34 (32.4%)
pathology
Family history of epilepsy 25 (17.1%) 4 (9.8%) 21 (20%)
Follow up duration (month) 32±24 35.3±27.3 30.7±22.4
Duration of medication  24±22 29.1±26.4 21.8±20.3
(month)
Table 1. Demographic and clinical characteristic of subjects
(n=146)
Fig. 1. Proportion of patients stayed on the initial AED at 24, 36,
and 48 months. In the CBZ group, the proportion of patients kept
on CBZ was 40.4%, 26.6%, and 14.9% at 24, 36, 48 months, res-
pectively, and 47.7%, 31.8%, and 25.0% in the TPM groups. TPM
tends to be continued in higher proportion of patients, but is not
statistically different from CBZ.
CBZ, carbamazepine; TPM, topiramate; AED, antipileptic drug.
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Fig. 2. Cumulative survival of topiramate (TPM) and carbamazepine
(CBZ). The retention rates of TPM and CBZ were compared over
48 months or longer. TPM seemed to have a better retention rate,
but was not significantly different from CBZ.
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Fig. 3. Comparative efficacy between CBZ and TPM. At 6 months
after starting the antiepileptic drug, 58.5% in the TPM group and 54.3%
in the CBZ group became seizure free and the average monthly
seizure frequency was decreased by 50% or more in 14.6% of the
TPM group and 8.6% of the CBZ group respectively. The findings
suggest that TPM is as efficacious as CBZ.
Grade A, seizure freedom; Grade B, seizure reduction of average
monthly frequency ≥50%; Grade C, seizure reduction of average
monthly frequency 25-50%; Grade D, seizure reduction of average
monthly frequency ≤25%; Grade E, no improvement in seizures;
Grade F, worsening of seizures.
CBZ, carbamazepine; TPM, topiramate; AED, antipileptic drug.
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Based on the reduction rate of the average monthly seizure
frequency, the efficacy was defined by Grade A-F. Grade A
was seizure free, Grade B for seizure reduction more than 50%,
Grade C for 25-50% of seizure reduction, Grade D for less
than 25% of seizure reduction, Grade E for no improvement,
and Grade F for when the seizures worsened. At 6 months,
Grade A and B patients were 73.1% for the TPM group, and
62.9% for the CBZ group (Fig. 3). 
As far as the side effects are concerned, 28 out of the sub-
jects (19.2%) showed side effects which consisted of 24.4%
for the TPM group and 17.1% for the CBZ group. No sta-
tistically significant difference was noted between the two
groups (odd ratio [OR]=1.559, 95% confidence interval [CI]=
0.650-3.740). 
The most common side effects included sleepiness and psy-
chomotor retardation for the TPM group and sleepiness and
rash for the CBZ group. Other side effects are summarized
in Fig. 4. The main reasons for discontinuing the drugs were
ineffectiveness (TPM; 12.2%, CBZ; 22.9%) and side effects
(TPM 2.4%, CBZ; 6.7%) (Fig. 5).
DISCUSSION
Many studies showed that TPM has a broad spectrum of
antiepileptic effects without any potentially dangerous side
effects in children (6, 11-16). In contrast to previous studies,
we investigated the long term retention rate, the efficacy, and
tolerability of TPM compared with CBZ in children with
epilepsies, particularly infants in the present study. We admit
some limitations and bias such as patient selection, diagnos-
tic tools, choosing the first AED for certain types of seizures,
etc. However, this study may provide the clinical evidence
in a certain aspect and can be helpful for clinicians. 
The data of 146 children under the age of 2 yr with a wide
spectrum of epilepsy were reviewed. We focused on the long-
term retention rate and adverse events of TPM compared with
CBZ. There was no obvious difference between the two groups
in demographic and clinical manifestations, but the TPM
group had more children with epileptic syndromes or symp-
tomatic epilepsies than the CBZ group (38.5% in CBZ group
vs. 53.4% in TPM group).
For evaluating the efficacy, the two groups were observed
for seizure freedom or seizure reduction >50% for 6 months
or longer. At 6 months after starting the AEDs, about half
of patients in both groups became seizure free. At least 50%
or more reduction of the average monthly seizure frequency
was achieved in 14.6% of the TPM group and 8.6% of the
CBZ group respectively. This result is not statistically sig-
nificant, but we still believe that TPM is more efficacious
than CBZ because TPM was given more for the patients with
symptomatic epilepsies or epileptic syndromes.
Fig. 5. The main reason of discontinuation of AEDs. The leading
causes were lack of efficacy (12.2% for TPM, 22.9% for CBZ) and
adverse events (2.4% for TPM, 6.7% for CBZ). Others included
deaths from acute illnesses, the poor compliance and so on. No
statistically significant difference was noted between two groups.
CBZ, carbamazepine; TPM, topiramate; AED, antipileptic drug.
Adverse events
Low efficacy
Others
A
Anhidrosis 1
Hyperactivity 1
Poor oral intake 2
Sleepiness &
psychomotor
retardation 7 Nausea/
vomiting 1
B
Hair loss 1
Skin rash 4
Diarrhea 1 
Nausea/vomiting 1 Poor oral intake 1
Sleepiness 11
↑ ↑ Liver
enzyme 2
Fig. 4. Adverse events of TPM (A) and CBZ (B). There were 12 events of side effects in 10 of 41 patients treated with TPM. In CBZ treated
patients, there were 21 events of side effects in 18 of 105 patients. The most common adverse events were CNS-related in both groups and
anhidrosis was another noticeable adverse event in the TPM group. 
CBZ, carbamazepine; TPM, topiramate.
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Like other previous studies (17-19), our study also demon-
strated that TPM had a similar retention rate over 48 months
or longer on survival analysis as compared with CBZ. Since
long-term retention rates indicate both effectiveness and tol-
erability, it may be concluded that TPM is as good as CBZ
for treating children under the age of 2 yr. In addition, TPM
may have a better efficacy at the expense of some deleterious
effects in our study because it was discontinued mainly due
to adverse events, not ineffectiveness during the study peri-
od, which differs from CBZ.
Based on previous studies, adverse events from TPM include
behavioral and cognitive difficulties, anorexia, weight loss,
irritability, allergic skin reaction, headaches, paraesthesia and
so on. They are usually mild, transient, and often related to
rapid titration (7, 8, 20-23). Despite the slow titration, 10 of
41 children (24.4%) in the TPM group suffered from adverse
events early during the treatment in this study. When com-
pared with the CBZ group, TPM showed similar side effects,
and they were mild and resolved with time or by adjusting
dosages. The most common side effects were CNS related
symptoms or signs, such as sleepiness and psychomotor retar-
dation. However, this assumption is limited because most
of children at this age cannot complain about them and these
symptoms can easily be overlooked.
Recent studies reported that anhidrosis was a relatively com-
mon side effect of TPM in children and adults (24, 25). In this
study, only one of 41 children complained of difficulty with
sweating or febrile sensation, which is quite comparable to
previous studies. Despite the fact, this side effect can be prob-
lematic especially in infants. It therefore should be more cau-
tious when prescribing TPM for an infant in a hot environment.
Monotherapy is known to be effective with minimal side
effects (26). In this study, 13 of 41 children in the TPM groups
were treated with monotherapy. They achieved seizure free-
dom without any harmful adverse events. This study sug-
gests TPM monotherapy would be applicable to treat infants
or toddlers with a variety of epilepsies. 
Finally, there are limited options of AEDs for managing
children with refractory epilepsies under the age of 2 yr. TPM
can be considered as a treatment option before moving onto
surgical or other treatment modalities. 
In conclusion, this comparative study had some limitations,
but showed the evidence that TPM was as effective as CBZ.
TPM did not cause serious side effects in managing children
with a variety of different epilepsies under the age of 2 yr.
As a result, TPM can be considered as one of major treatment
options, preferably monotherapy for treating infants with
epilepsies. 
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